25 Jan 2012

TREND 1: Addressing Trial Complexity

by Lori Shields

Understanding clinical trial complexity will become more of a focus in 2012 as sponsors seek new ways to manage costs and speed study execution. It’s imperative to understand the impact that a more complex study design has on the success of the trial, particularly on the critical metrics of recruitment and retention of sites and subjects alike. We’ve seen significant growth in the complexity of study design globally, which requires more effort on the part of sites participating, but due to restrained budgets, sites are not always offered competitive reimbursement.

Our data on over 250,000 actual study grants around the world shows us a troubling trend in some US regions. Reimbursement rates for participating sites in the Northeast and Pacific regions have increased, but not enough to offset the high level of work and expertise required by increasing complex studies. Budget-focused sponsors have not appropriately factored in the amount of work that must be performed on a patient, how long it takes, the level of expertise required by the doctors or site staff, as well as the amount of data collected and the required data monitoring. If sites aren’t offered proper compensation for their efforts, sponsors are going to have a hard time recruiting them, putting study timelines at risk.

During study acceptance and the budget negotiation process, a site takes into account many factors and may make a decision to accept what might be considered a lower compensation for a particular study, especially if the drug or device shows promise to their patients. However, in a highly competitive situation, sites will be more apt to work with sponsors who take the complexity of the study design into account with respect to both reimbursement and timelines.

Complexity has a big impact on patient recruitment as well. With social media, patients have access to more and more information about studies available to them. A savvy patient might opt for a study that requires less of their time and fewer onerous procedures, such as blood work for the needle-phobe. I’ve even heard of sponsors getting patient input during the protocol review process—as a way to understand patient tolerance, eliminate unnecessary procedures, predict enrollment and potentially decrease dropout rates. I predict that this particular idea will spread farther in 2012 and I’m eager to see the resulting changes to complex study designs.

More about Lori Shields

Related posts

Protocol Interpretation: Is There a Better Way?

I have spent a significant portion of the last 12 ...

Amgen Team Discuss Study Design, Data Monitoring and Clinical Integrations at 2012 A-MUG

In this three-part video series, Amgen team members Theresa Robertson, ...

Continuing the Conversation: A Follow-Up to Our “Optimizing Study Design and Protocol Developm ...

Guest blogger Ken Getz recently shared some compelling findings from ...

European Medidata User Group Going from Strength to Strength

It was during a meeting with Medidata Solutions at Orion ...

0

Comments in this post

  • There are no comments yet. You can be the first to leave a comment.

Leave a reply

274---274

FDA Wants Your mHealth Clinical Tri ...

FDA has a message for sponsors that ...

The Value Proposition for mHealth i ...

We had a chance to catch up with ...

Five Considerations For Wearable De ...

Craig Lipset leads Pfizer’s clini ...

How Does Risk-based Monitoring Impa ...

[caption id="attachment_1913" align ...

The Data-driven Protocol Design

Dave Gemzik, Medidata’s Princ ...

Ann on Taking ePRO to New Places – Replacing Paper
Excellent article!

David Detwiler on “Painful Memories” – How Memory Biases Affect Patient-reported Outcome Measures
In a way the patients memories are accurate if you think of them remembering "average pain" rather than "peak pain"...

Sam on Taking ePRO to New Places – Replacing Paper
Clear and concise description of Patient Cloud cost benefits vs. Paper. Used it today!

Khrystal Davis on What Advocates Said to Congress During Rare Disease Week on the Hill
Great post Steve. I am mother to Hunter, a RARE terminal ill three year old with SMA Type 1. I'm...

Penelope Manasco on Are Your Data Cleaning Cycle Times Out of Control?
Steve, I'm confused about this graph. You say that time from visit to query close is in the 30 day...